Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05705401 · ClinicalTrials.gov registry record · Phase 3
Testing Radiation and HER2-targeted Therapy Versus HER2-targeted Therapy Alone for Low-risk HER2-positive Breast Cancer
A Phase 3 study of HER2-positive Breast Cancer, sponsored by NRG Oncology.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 1,300
- Enrollment target
- 20
- Study locations
NCT05705401 is a Phase 3 study of HER2-positive Breast Cancer that is actively recruiting participants, run by NRG Oncology. The registered enrollment target is 1,300 participants, above the 216-participant average among 54 other HER2-positive Breast Cancer trials with a reported enrollment target (502% higher). The trial reports 20 study locations across 3 states.
The verdict
NCT05705401, a Phase 3 study of HER2-positive Breast Cancer, is actively recruiting participants, sponsored by NRG Oncology.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 1,300 participants
- Enrollment target
- 20
- Study locations
Study Summary
This Phase III trial compares the recurrence-free interval (RFI) among patients with early-stage, low risk HER2+ breast cancer who undergo breast conserving surgery and receive HER2-directed therapy, and are randomized to not receive adjuvant breast radiotherapy versus those who are randomized to receive adjuvant radiotherapy per the standard of care.
Conditions Studied
Interventions
- RADIATION Standard of Care Adjuvant Breast Radiation
- DRUG Standard of Care HER2-targeted Therapy Without Adjuvant Breast Radiation
Study Locations (20)
California
- Kaiser Permanente-Deer Valley Medical Center - Antioch
- Mission Hope Medical Oncology - Arroyo Grande - Arroyo Grande
- PCR Oncology - Arroyo Grande
- Sutter Auburn Faith Hospital - Auburn
- Sutter Cancer Centers Radiation Oncology Services-Auburn - Auburn
- Tower Cancer Research Foundation - Beverly Hills
- Sutter Cancer Centers Radiation Oncology Services-Cameron Park - Cameron Park
- City of Hope Comprehensive Cancer Center - Duarte
- Kaiser Permanente Dublin - Dublin
- Kaiser Permanente-Fremont - Fremont
- Palo Alto Medical Foundation-Fremont - Fremont
- Fresno Cancer Center - Fresno
- Kaiser Permanente-Fresno - Fresno
- UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care - Irvine
- City of Hope at Irvine Lennar - Irvine
- City of Hope Antelope Valley - Lancaster
Arizona
- Cancer Center at Saint Joseph's - Phoenix
- Banner University Medical Center - Tucson - Tucson
- University of Arizona Cancer Center-North Campus - Tucson
Arkansas
- NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro - Jonesboro
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,300 participants |
| Start Date | 2023-03-13 |
| Est. Completion | 2037-02-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05705401
The ClinicalTrials.gov registry entry for NCT05705401 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 1,300 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 216-participant average among 54 other HER2-positive Breast Cancer trials with a reported enrollment target (502% higher). The listed sponsor is NRG Oncology, which has 64 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with HER2-positive Breast Cancer appearing as the primary indexed condition, and to 2 interventions - of which Standard of Care Adjuvant Breast Radiation is the first listed.
NCT05705401 reports 20 study locations spanning 3 distinct geographic areas - top geographies include California, Arizona, Arkansas.
Frequently Asked Questions
What is clinical trial NCT05705401 about?
NCT05705401 is a clinical study titled "Testing Radiation and HER2-targeted Therapy Versus HER2-targeted Therapy Alone for Low-risk HER2-positive Breast Cancer". This Phase III trial compares the recurrence-free interval (RFI) among patients with early-stage, low risk HER2+ breast cancer who undergo breast conserving surgery and receive HER2-directed therapy, and are randomized to not receive adjuvant breast radiotherapy versus those who are randomized to re...
What is the current status of trial NCT05705401?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 1,300 participants. The study started on 2023-03-13. Estimated completion is 2037-02-01.
What conditions does trial NCT05705401 study?
This clinical trial studies the following conditions: HER2-positive Breast Cancer.
What interventions are being tested in trial NCT05705401?
The interventions under investigation include: Standard of Care Adjuvant Breast Radiation (RADIATION), Standard of Care HER2-targeted Therapy Without Adjuvant Breast Radiation (DRUG).
Who is sponsoring clinical trial NCT05705401?
This trial is sponsored by NRG Oncology, which has 64 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05705401 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HER2-positive Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer
ACTIVE NOT RECRUITING · Phase 3
-
A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer
ACTIVE NOT RECRUITING · Phase 3
-
The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer
RECRUITING · Phase 2
-
TRUDI: TDXD+Durva in HER2+/Low IBC
RECRUITING · Phase 2
-
HERizon-Breast: A ctDNA-Guided Adaptive Study of Sequential Anti-HER2 Therapies and CNS Prophylaxis to Induce Long-Term Remission
RECRUITING · Phase 2
-
A Phase 1/1b Study of IAM1363 in HER2 Cancers
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.